Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue
This article is powered by The Rose Sheet
Executive Summary
FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.